Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pulmatrix Operating Company Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions involve 2 distinct examiners and 2 distinct art units. AL-AWADI, DANAH J is the busiest examiner, with 1 busiest examiner pending action. The distribution of 2 pending office actions across 2 distinct art units indicates that the company's current patenting efforts touch upon different sub-specialties within Biotechnology & Pharmaceuticals.
Having 2 distinct examiners means the company is receiving feedback from multiple sources at the USPTO. This requires a prosecution strategy that can adapt to the specific requirements of 2 distinct examiners. The presence of 2 distinct art units suggests that the intellectual property is not confined to a single narrow classification. AL-AWADI, DANAH J manages 1 busiest examiner pending action, which represents a portion of the current pending workload. This level of diversity in the portfolio necessitates careful coordination across different examination groups. The 2 pending office actions provide a baseline for the company's current engagement with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 52.4% | +34.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17048491 | ANTIFUNGAL FORMULATIONS FOR PULMONARY ADMINISTRATION COMPRISING ITRACONAZOLE | ABBAS, ABDULRAHMAN MUSTAFA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17048491 | ANTIFUNGAL FORMULATIONS FOR PULMONARY ADMINISTRATION COMPRISING ITRACONAZOLE | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | — | Pending | Oct 16, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial